Results 131 to 140 of about 6,042 (221)

IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far? [PDF]

J Inflamm Res
Megna M, D'Agostino M, Feo F, Ventura V, Tommasino N, Potestio L.   +5 more
europepmc   +1 more source

Factors Predicting Guselkumab Treatment Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of Korean Real-World Data. [PDF]

J Clin Med
Lee YB, Shin BS, Kim M, Suh MK, Youn SW, Lee JY, Kim CW, Lee GY, Kim KH, An J, Kim Y, Kim KJ, Kim DH, Son SW.   +13 more
europepmc   +1 more source

A 76-week real-world multidimensional analysis of guselkumab in moderate to severe plaque psoriasis: a retrospective cohort study based on Chinese clinical practice standards. [PDF]

Front Immunol
Hu R, Li Q, Liu X, Hu Y, Pan Y, Liu C, Lu P, Chen X, Xiong J, Zhang J, Huang K.   +10 more
europepmc   +1 more source

Update on psoriasis immunopathogenesis and targeted immunotherapy [PDF]

core   +1 more source

Dual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature. [PDF]

SAGE Open Med Case Rep
Muylaert Barrett B, Music M, Yadav G.
europepmc   +1 more source

Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis. [PDF]

Rheumatology (Oxford)
Marzo-Ortega H, McInnes IB, Sharaf M, Zabotti A, Rampakakis E, McGonagle D, Abogamal A, Richette P, Schett G.   +8 more
europepmc   +1 more source

Early and Mid-Term Ultrasound Response to Guselkumab in Psoriatic Arthritis: A Real-World Cohort from a Single Tertiary Rheumatology Center. [PDF]

J Clin Med
Messina F, Caimi M, Lucchetti L, Bonifacio M, Fiorino E, Conforti A.   +5 more
europepmc   +1 more source

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors. [PDF]

Adv Ther
Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF.   +13 more
europepmc   +1 more source

Case Report: Successful management of refractory SAPHO syndrome with guselkumab-upadacitinib combination. [PDF]

Front Immunol
Jin D, Xu MY, Wang XL, Wang RQ, Tang JT, Liu YQ.   +5 more
europepmc   +1 more source

New-onset ulcerative colitis temporally associated with with ixekizumab in a psoriasis patient successfully treated with guselkunmab: A case report. [PDF]

Medicine (Baltimore)
Tang J, Li W, Zhang H.
europepmc   +1 more source